-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Investors Might Be Losing Patience for Apellis Pharmaceuticals' (NASDAQ:APLS) Increasing Losses, as Stock Sheds 7.4% Over the Past Week
Investors Might Be Losing Patience for Apellis Pharmaceuticals' (NASDAQ:APLS) Increasing Losses, as Stock Sheds 7.4% Over the Past Week
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a really great company, you can more than double your money. For instance the Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) share price is 145% higher than it was three years ago. How nice for those who held the stock! Also pleasing for shareholders was the 42% gain in the last three months.
Although Apellis Pharmaceuticals has shed US$550m from its market cap this week, let's take a look at its longer term fundamental trends and see if they've driven returns.
See our latest analysis for Apellis Pharmaceuticals
Apellis Pharmaceuticals isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.
Over the last three years Apellis Pharmaceuticals has grown its revenue at 63% annually. That's much better than most loss-making companies. Meanwhile, the share price performance has been pretty solid at 35% compound over three years. But it does seem like the market is paying attention to strong revenue growth. Nonetheless, we'd say Apellis Pharmaceuticals is still worth investigating - successful businesses can often keep growing for long periods.
The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).
NasdaqGS:APLS Earnings and Revenue Growth September 18th 2022Apellis Pharmaceuticals is well known by investors, and plenty of clever analysts have tried to predict the future profit levels. Given we have quite a good number of analyst forecasts, it might be well worth checking out this free chart depicting consensus estimates.
A Different Perspective
Pleasingly, Apellis Pharmaceuticals' total shareholder return last year was 83%. That's better than the annualized TSR of 35% over the last three years. The improving returns to shareholders suggests the stock is becoming more popular with time. It's always interesting to track share price performance over the longer term. But to understand Apellis Pharmaceuticals better, we need to consider many other factors. For example, we've discovered 2 warning signs for Apellis Pharmaceuticals that you should be aware of before investing here.
But note: Apellis Pharmaceuticals may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
你在任何一只股票上最多只能损失100%的钱(假设你不使用杠杆)。但如果你购买一家真正伟大的公司的股票,你可以更多也不愿让你的钱翻倍。例如,阿佩利斯制药公司纳斯达克(APLS:APLS)股价比三年前高出145%。对于那些持有股票的人来说,这是多么好的一件事!同样令股东高兴的是,过去三个月的涨幅为42%。
尽管Apellis PharmPharmticals本周市值缩水5.5亿美元,但让我们看看其较长期的基本面趋势,看看它们是否推动了回报。
查看我们对Apellis制药公司的最新分析
Apellis PharmPharmticals目前没有盈利,因此大多数分析师都会关注收入增长,以了解基础业务的增长速度。当一家公司没有盈利时,我们通常预计会看到良好的收入增长。正如你可以想象的那样,快速的收入增长,如果保持下去,往往会带来快速的利润增长。
在过去的三年里,阿佩利斯制药公司的收入以每年63%的速度增长。这比大多数亏损的公司要好得多。与此同时,该公司股价表现相当稳健,三年来的复合收益率为35%。但看起来市场确实在关注强劲的收入增长。尽管如此,我们仍然认为阿佩利斯制药公司仍然值得研究--成功的企业往往可以保持长期增长。
下图描述了收益和收入随时间的变化(通过单击图像来揭示确切的价值)。
NasdaqGS:APLS收益和收入增长2022年9月18日Apellis PharmPharmticals为投资者所熟知,许多聪明的分析师曾试图预测未来的利润水平。鉴于我们有相当多的分析师预测,可能很值得查看以下内容免费描绘共识估计的图表。
不同的视角
令人欣喜的是,Apellis PharmPharmticals去年的总股东回报率为83%。这比过去三年35%的年化TSR要好。股东回报的提高表明,随着时间的推移,该股正变得越来越受欢迎。跟踪股价的长期表现总是很有趣的。但为了更好地了解阿佩利斯制药公司,我们需要考虑许多其他因素。例如,我们发现阿佩利斯制药公司的2个警告标志在这里投资之前你应该意识到这一点。
但请注意:Apellis PharmPharmticals可能不是最值得购买的股票。所以让我们来看看这个免费过去有盈利增长(以及进一步增长预测)的有趣公司名单。
请注意,本文引用的市场回报反映了目前在美国交易所交易的股票的市场加权平均回报。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧